Tempest Therapeutics Inc

NASDAQ TPST

Data sourced from

and

Download Data

Tempest Therapeutics Inc Non-current Assets to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2024: 0.25

Tempest Therapeutics Inc Non-current Assets to Total Assets Ratio is 0.25 for the Trailing 12 Months (TTM) ending March 31, 2024, a 37.57% change year over year. The non-current assets to total assets ratio measures the proportion of a company's non-current assets to its total assets. It is calculated by dividing the total non-current assets by the total assets. This ratio provides insights into the composition of a company's asset base and the extent to which it relies on non-current assets, such as property, plant, and equipment, to generate revenue. A higher ratio suggests a greater proportion of non-current assets, indicating potential long-term stability and investment in fixed assets.

Tempest Therapeutics Inc Non-current Assets to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.18, a 178.15% change year over year.
Tempest Therapeutics Inc Non-current Assets to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 0.06, a -18.81% change year over year.
Tempest Therapeutics Inc Non-current Assets to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 0.08, a 31.64% change year over year.
Tempest Therapeutics Inc Non-current Assets to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was 0.06, a 142.08% change year over year.

NASDAQ: TPST

Tempest Therapeutics Inc

CEO	Mr. Stephen R. Brady J.D., LLM
IPO Date	Nov. 12, 2012
Location	United States
Headquarters	7000 Shoreline Court, South San Francisco, CA, United States, 94080
Employees	17
Sector	Healthcare
Industry	Biotechnology

Description

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

Key trends